Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 29% Improvement Relative Risk HRQoL score -28% c19early.org/pl Shao et al. Paxlovid for COVID-19 LATE TREATMENT Is late treatment with paxlovid beneficial for COVID-19? Retrospective 1,082 patients in China (December 2022 - February 2023) Lower mortality with paxlovid (not stat. sig., p=0.16) Shao et al., medRxiv, doi:10.1101/2023.05.10.23289325 Favors paxlovid Favors control

Composite interventions on outcomes of severely and critically ill patients with COVID-19 in Shanghai, China

Shao et al., medRxiv, doi:10.1101/2023.05.10.23289325
Shao et al., Composite interventions on outcomes of severely and critically ill patients with COVID-19 in Shanghai, China, medRxiv, doi:10.1101/2023.05.10.23289325
May 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,082 hospitalized COVID-19 patients in China, showing lower mortality and worse quality of life with paxlovid.
Confounding by contraindication. [Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
risk of death, 29.0% lower, HR 0.71, p = 0.16, treatment 280, control 802, day 60.
relative HRQoL score, 28.3% worse, RR 1.28, p < 0.001, treatment mean 0.46 (±0.42) n=237, control mean 0.59 (±0.41) n=456, day 60.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shao et al., 14 May 2023, retrospective, China, peer-reviewed, 9 authors, study period 8 December, 2022 - 9 February, 2023.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit